Since this clinical study was performed with only nine cases, an increased number of patients should be further required to conclude whether ALOX12 is a valuable biomarker for developing epigenetic evidence-based therapeutics by AZA in MDS. This evidence concerns the gene ALOX12 and myelodysplastic syndrome.